No Data
No Data
No Data
No Data
No Data
Actym Therapeutics Appoints Thomas Smart As CEO >ANAB
Actym Therapeutics Appoints Thomas Smart As CEO >ANAB
Dow JonesApr 24 21:00
AnaptysBio Initiated at Outperform by Leerink Partners
AnaptysBio Initiated at Outperform by Leerink Partners
Dow JonesApr 17 00:20
AnaptysBio (ANAB.US) was first covered by Leerink Partners, which gave it an superior market rating, with a target price of $47.00.
AnaptysBio (ANAB.US) was first covered by Leerink Partners, which gave it an superior market rating, with a target price of $47.00.
Zhitong FinanceApr 17 00:11
Leerink Partners Initiates Coverage On AnaptysBio With Outperform Rating, Announces Price Target of $47
Leerink Partners analyst David Risinger initiates coverage on AnaptysBio with a Outperform rating and announces Price Target of $47.
Analyst UpgradesApr 17 00:10
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
The Motley FoolApr 13 07:00
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ:FAST) fell sharply during Thursday's session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9
BenzingaApr 12 01:33
No Data
No Data